Immune checkpoint blockade proved to be efficient when targeting CXCR2 in parallel, significantly increasing animal survival by reducing the proliferation tumor rates as well as enhancing the proportion of both CD4+ and CD8+ T cells while diminishing Tregs. This evidence concerns the gene CD4 and neoplasm.